Other languages Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
38.73 ^USD	+1.28%		+0.94%	+91.26%

May. 15	Transcript : Tarsus Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:55 PM
May. 09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
BioPharma Credit to loan USD100 million to Tarsus Pharmaceuticals	Apr. 24
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	Mar. 27
Tarsus Pharmaceuticals Prices $100 Million Public Offering	Mar. 01
Tarsus Pharmaceuticals' Q4 Net Loss Widens, Revenue Increases	Feb. 27
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Tarsus Announces Positive Topline Results from Carpo, A Phase 2A Proof-Of-Concept ?Tick-Kill? Trial Evaluating Tp-05 for the Prevention of Lyme Disease	Feb. 22
Tarsus Pharmaceuticals, Inc. Announces Executive Changes	Jan. 18
Tarsus Pharmaceuticals Insider Sold Shares Worth $810,623, According to a Recent SEC Filing	Dec. 22
Tarsus Pharmaceuticals Says Phase 2a Trial of TP-03 in Meibomian Gland Disease Yields Positive Results	Dec. 11
Tarsus Pharmaceuticals, Inc. Announces Positive Topline Results from the Ersa Phase 2A Clinical Trial Evaluating Tp-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites	Dec. 11
Tarsus Pharmaceuticals Insider Sold Shares Worth $136,286, According to a Recent SEC Filing	Dec. 01
Tarsus Pharmaceuticals Insider Sold Shares Worth $136,270, According to a Recent SEC Filing	Dec. 01
Tarsus Pharmaceuticals Insider Sold Shares Worth $146,933, According to a Recent SEC Filing	Nov. 17
Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Tarsus Pharmaceuticals Insider Sold Shares Worth $105,920, According to a Recent SEC Filing	23-10-20
Tarsus Pharmaceuticals Shares Fall; CEO Sold Stock	23-09-25
Tarsus Pharmaceuticals Insider Sold Shares Worth $137,680, According to a Recent SEC Filing	23-09-22
Insider Sell: Tarsus Pharmaceuticals	23-08-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Other languages

Filters